Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Blackrock Inc (BLK) vs Cassava Sciences Inc (FLNA) Price & Performance

Blackrock IncTrade
Cassava Sciences IncTrade

Price performance (Past 24H)

Key statistics

Blackrock Inc vs Cassava Sciences Inc — how do they compare? Blackrock Inc trades at $1,148.83 (market cap $175.22B), while Cassava Sciences Inc trades at $0.97 (market cap $47.75M). The key difference: Blackrock Inc is far larger — about 3669.5× Cassava Sciences Inc's market cap, and Blackrock Inc pays a 2.03% dividend while Cassava Sciences Inc pays none. Which is the better fit depends on your goals.

BLKFLNA
Market Cap
$175.22B$47.75M
Volume
641,547
Sector
FinancialsHealth
52-Week High
$1.20K$4.64
52-Week Low
$922.90$0.87
Enterprise Value
$176.32B-$34.93M
Dividend Yield
2.03%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Blackrock Inc

BlackRock (BLK) trades at $1,136.39, up 0.63% with strong technical momentum and bullish moving average signals. The company demonstrates robust fundamentals with revenue growth from $20.4B in 2024 to $24.2B in 2025, though net income margin compressed to 22.93%. Recent earnings beats and a 78.79% analyst buy rating support positive sentiment, while the stock trades near resistance at $1,144.

BLK presents a compelling investment case with consistent earnings outperformance and strong institutional support, though investors face risks from margin compression and legal scrutiny. The consensus price target of $1,350 suggests 18.8% upside potential, balanced by overbought technical indicators and competitive pressures in asset management.

Cassava Sciences Inc

FLNA trades at $0.995, up 3.75% today, with a bearish technical signal from moving averages but neutral oscillators. The company reported three consecutive quarterly earnings beats, with Q2 2026 EPS of -$0.18 beating expectations of -$0.225. Financials show negative cash flows and profitability, with ROE at -55.79% and net income of -$90.97M in 2025. Analyst consensus is strongly positive with 8 buy ratings out of 12.

Despite operational losses, FLNA's consistent earnings beats and strong analyst support suggest potential upside if clinical developments progress. Key risks include sustained cash burn, lack of revenue, and dependence on successful drug trials for Tuberous Sclerosis Complex. The stock remains speculative with high volatility expected.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Blackrock Inc

BlackRock, Inc. provides investment management services to institutional clients and to retail investors through various investment vehicles. The Company manages funds, as well as offers risk management services. BlackRock serves governments, companies, and foundations worldwide.

Read more on BLK

About Cassava Sciences Inc

Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease

Read more on FLNA